- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04915937
Formula Tolerance of Term Infants
December 19, 2022 updated by: Abbott Nutrition
Tolerance of Term Infants Fed Formula With Oligosaccharides
To assess the effects of infant formula with oligosaccharides on symptoms of formula intolerance in healthy, term infants
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85015
- MedPharmics, LLC
-
-
Florida
-
Miami, Florida, United States, 33126
- Dade Research Center, LLC
-
-
Georgia
-
Macon, Georgia, United States, 31210
- Meridian Clincial Research- Macan
-
-
Idaho
-
Idaho Falls, Idaho, United States, 83404
- Clinical Research Prime
-
-
Kentucky
-
Owensboro, Kentucky, United States, 42303
- Springs Medical Research
-
-
Louisiana
-
Covington, Louisiana, United States, 70433
- MedPharmics
-
-
Montana
-
Kalispell, Montana, United States, 59901
- Boeson Research Kalispell
-
-
Nebraska
-
Hastings, Nebraska, United States, 68901
- Meridian Clinical Research
-
Lincoln, Nebraska, United States, 68516
- Be Well Clinical Studies
-
-
Tennessee
-
Memphis, Tennessee, United States, 38115
- AVIATI Healthcare & Clinical Research
-
-
Texas
-
Edinburg, Texas, United States, 78539
- Invesclinic US LLC
-
League City, Texas, United States, 77573
- Maximos Ob/Gyn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 1 year (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participant is judged to be in good health as determined from participant's medical history by parent report
- Participant is a singleton from a full-term birth with a gestational age of 37-42 weeks.
- Participant's birth weight was >= 2490 g (~5 lbs. 8 oz.)
- Participant was identified by parents as very fussy or extremely fussy in the Baseline Tolerance Evaluation on a formula-feed
- Participant is exclusively formula-fed at time of study entry and Parent(s) confirm their intention to feed their infant the study product as the sole source of nutrition for the duration of the study, unless instructed otherwise by their healthcare professional.
- Parent(s) confirm their intention not to administer vitamin, mineral, human milk oligosaccharide(s) (HMO), prebiotic(s), or probiotic(s) supplements (with the exception of vitamin D supplements if instructed by their healthcare professional), non-study formula, foods, juices, or other sources of nutrition to their infant from enrollment through the duration of the study
- Participant's parent(s) has voluntarily signed and dated an Informed Consent Form (ICF), approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC) and provided applicable local privacy regulation authorization prior to any participation in the study
Exclusion Criteria:
- An adverse maternal, fetal, or participant medical history that is thought by the investigator to have potential for effects on tolerance, growth, and/or development. This includes but is not limited to suspected maternal substance abuse.
- Participant is taking and plans to continue taking medications (including OTC, such as Mylicon® for gas), home remedies (such as juice for constipation), herbal preparations, or rehydration fluids that might affect GI tolerance.
- Participant participates in another study that has not been approved as a concomitant study
- Participant has been fed a formula with greater than 2 HMOs prior to study enrollment
- Participant has been fed an extensively hydrolyzed, amino acid based, or preterm formula within 14 days prior to study enrollment and/or an extensively hydrolyzed, amino acid based, or preterm formula has been recommended by the physician.
- Participant has an allergy or intolerance to any ingredient in the study product, as reported by the parent
- Participant has been treated with antibiotics within 7 days prior to enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study Infant Formula
Feed ad libitum during study period
|
RTF milk-based infant formula with oligosaccharides
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fussiness
Time Frame: Baseline to Study Day (SDAY) 2
|
Absolute and % change in fussiness severity reported from Daily Tolerance Diary
|
Baseline to Study Day (SDAY) 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Gastrointestinal Tolerance
Time Frame: Baseline to SDAY 28
|
Parent Completed Diary
|
Baseline to SDAY 28
|
Stool
Time Frame: Baseline to SDAY 28
|
Parent Completed Diary
|
Baseline to SDAY 28
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Formula Intake
Time Frame: SDAY 1 to SDAY 28
|
Parent Completed Diary
|
SDAY 1 to SDAY 28
|
Weight
Time Frame: SDAY 1 to SDAY 28
|
Weight gains, percentiles, and z-scores
|
SDAY 1 to SDAY 28
|
Length
Time Frame: SDAY 1 to SDAY 28
|
Length gains, percentiles, and z-scores
|
SDAY 1 to SDAY 28
|
Infant Feeding and Stool Patterns Questionnaire
Time Frame: SDAY 1 and SDAY 28
|
Parent completed questionnaire; 16, 5-point Likert scale questions, scaled from frequent to less frequent
|
SDAY 1 and SDAY 28
|
Formula Satisfaction Questionnaire
Time Frame: SDAY 1 and SDAY 28
|
Parent completed questionnaire; 13 questions of up to 5 categories scaled from positive to negative
|
SDAY 1 and SDAY 28
|
Parental perspectives
Time Frame: SDAY 1 and SDAY 28
|
Parent completed questionnaire; 4, 5-point Likert scale questions, scaled from negative to positive
|
SDAY 1 and SDAY 28
|
Health Resource Utilization
Time Frame: SDAY 7 and SDAY 28
|
Number of Visits
|
SDAY 7 and SDAY 28
|
Adverse Events
Time Frame: SDAY 1 to SDAY 28
|
Standard adverse event reporting
|
SDAY 1 to SDAY 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Elizabeth Reverri, PhD, MS, RD, Abbott Nutrition
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 13, 2021
Primary Completion (Actual)
November 22, 2022
Study Completion (Actual)
November 22, 2022
Study Registration Dates
First Submitted
June 1, 2021
First Submitted That Met QC Criteria
June 1, 2021
First Posted (Actual)
June 7, 2021
Study Record Updates
Last Update Posted (Actual)
December 20, 2022
Last Update Submitted That Met QC Criteria
December 19, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- AL41
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastro-Intestinal Tolerance
-
Abbott NutritionTerminatedGastro-Intestinal ToleranceUnited States
-
Abbott NutritionCompletedGastro-Intestinal ToleranceUnited States
-
Abbott NutritionCompleted
-
Abbott NutritionCompleted
-
Abbott NutritionCompletedGastro-Intestinal ToleranceUnited Kingdom
-
Abbott NutritionWithdrawnGastro-intestinal Tolerance
-
Maastricht University Medical CenterCatharina Ziekenhuis EindhovenCompleted
-
Dana-Farber Cancer InstituteCompletedGastro Intestinal CancerUnited States
-
Danone ResearchEuraxi PharmaActive, not recruitingGastro-intestinal Symptoms in Healthy SubjectsFrance
Clinical Trials on Study Infant Formula
-
Abbott NutritionCompleted
-
Abbott NutritionCompleted
-
Jovie USA, LLCIQVIA RDS Inc.; ObvioHealthCompleted
-
Société des Produits Nestlé (SPN)University College, LondonCompletedGrowth | Infant FormulaUnited Kingdom
-
Nara OrganicsPaidion Research, Inc.Completed
-
Abbott NutritionCompleted
-
Société des Produits Nestlé (SPN)Completed